Lucy Scientific Discovery Inc., an early stage psychotropics contract manufacturing company, engaged in the research, manufacturing, and commercialization of psychedelic products. The company offers biological raw materials, active pharmaceutical ingredients (APIs), and finished biopharmaceutical products. It also develops and produces highly controlled agricultural grow environments for plant manufacturing and replication applications. The company was formerly known as Hollyweed North Cannabis Inc. and changed its name to Lucy Scientific Discovery Inc. in May 2021. Lucy Scientific Discovery Inc. was incorporated in 2017 and is headquartered in Victoria, Canada.
Stock data | 2023 | Change |
---|---|---|
Price | $0.02 | N/A |
Market Cap | $254.02K | N/A |
Shares Outstanding | 12.70M | -21.98% |
Employees | 2.00 | N/A |
Shareholder Equity | 4.68M | -197.93% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | -0.03 | N/A |
P/S Ratio | 36.04 | N/A |
P/B Ratio | 0.05 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -1.9211 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $7.05K | N/A |
Earnings | -$8.99M | N/A |
EPS | -0.71 | N/A |
Earnings Yield | -35.50 | N/A |
Gross Margin | 0.3615 | N/A |
Operating Margin | -818.01 | N/A |
Net income margin | -1.28K | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $8.78M | N/A |
Total Debt | $1.79M | N/A |
Cash on Hand | $1.67M | N/A |
Debt to Equity | 0.8762 | -144.49% |
Cash to Debt | 0.9358 | 5055.10% |
Current Ratio | $1.41 | 331.60% |